A call to action — FDA encouraging development of new IBS therapies: 4 key notes

There's a great medical need for new therapies aimed at treating irritable bowel syndrome, according to FDA gastroenterologist Tara Altepeter, MD.

Here's what you should know:

1. The FDA is working at bringing more IBS-facing treatments to the market, after the emergence of new research.

2. It's estimated that 15.3 million people or 20 percent of all Americans suffer from IBS. With unassuming symptoms, the disease often goes undiagnosed.

3. Treatments vary widely for IBS patients. For some changes in diet, nutrition and exercise can manage symptoms, while others use medication to manage their IBS. There is no cure for IBS.

4. The FDA wants to bring more treatments to the market to help the affected population better manage their IBS.

More articles on gastroenterology:
University of Arizona researchers making dual-view endoscope: 3 key notes
Payment Model Technical Advisory Committee approves Project Sonar as an alternative payment model
GI leader to know: Dr. Brent Gray of Central Texas Gastroenterology Consultants

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months